Experimental study on adoptive immunotherapy for malignant glioma with peripheral blood mononuclear cells(PBMC) Induced by PHA, CD3 and IL-2

Objective To investigate a new clinical therapeutic approach for adoptive immunotherapy as malignant gliomas. Methods In this study, a new type of killer cells, named PHA CD3AK cells was induced by means of costimulating peripheral blood mononuclear cells with phytohemagglutinim (PHA), anti CD3 monoclonal antibody (CD3) and Interleukin 2(IL 2), Its biological characteristics were compared with the control group, named CD3AK cells, induced by means of stimulating PBMC with CD3 and IL 2.Results Both PHA CD3AK cells and CD3AK cells, performed the highest proliferation during the 6th day of culture. It is obvious that the amount of proliferation of PHA CD3 cells is higher than that of CD3AK cells P0 05). The actual multiplication fold of the former is much more than that of the control group. Moreover, PHA CD3AK cells gained an advantage over the control group in cytotoxicity against malignant glioma cells (BT325) during the 6th, 7th and 8th day of cuture (P0 05). Conclusions As a new type of killer cells, PHA CD3AK cells have some advantages over the control group CD3AK cells in proliferation, cytotoxicity against BT325, and the utilizing amount of IL 2, indicating the synergistic enhancing role of PHA, CD3 and IL 2. The application of PHA CD3AK cells might open a new prospect to clinical therapeutic approach for maligant gliomas.